Platform Prints First Collagen-Based Bioink for Personalized Tissue Creation

Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. 

Conexeu said their CXU™ platform, a bovine-derived, functional extracellular matrix that mimics the structure and behavior of native human tissue,platform successfully printed collagen-based scaffolds that the body recognizes as native tissue, helping with neovascularization and potentially serving as a foundation for personalized implants in craniofacial, breast, periodontal, and other soft-tissue reconstructions. 

“This could be a game changer in the fields of aesthetics and tissue reconstruction,” said Claudia Chavez-Munoz, MD, PhD, Conexeu’s Chief Science Officer, said in the news release. “By showing that CXU™ can print tissue structures, we are opening the door to truly personalized implants and grafts.”

The manufacturer said the technology creates a unified platform that functions as an injectable regenerative material and also as a printable bioink, adding that an FDA approval would position the company as a leader in bioinks.

“This breakthrough is a declaration,” said Miles Harrison, President & CEO of Conexeu, in the news release. “The future of medicine is not just repairing tissue; it is creating it. With CXU™, we can inject regeneration today, and we can design regeneration for tomorrow. This is the dawn of personalized tissue on demand. CXU™ prints with precision but lives like biology and it sets the stage for a completely new era of human reconstruction.”

Source: Conexeu Sciences press release. November 20, 2025.